1 Year Total Returns (Daily) Chart

View 1 Year Total Returns (Daily) for NGNE.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View 1 Year Total Returns (Daily) Chart
Start Trial

Historical 1 Year Total Returns (Daily) Data

View and export this data back to 2015. Start Trial.
Date Value
September 25, 2026 62.65%
September 24, 2026 81.16%
September 23, 2026 83.56%
September 22, 2026 97.88%
September 21, 2026 89.36%
September 18, 2026 71.79%
September 17, 2026 83.00%
September 16, 2026 98.80%
September 15, 2026 93.07%
September 14, 2026 85.32%
September 11, 2026 76.69%
September 10, 2026 94.19%
September 09, 2026 96.78%
September 08, 2026 96.04%
September 04, 2026 96.84%
September 03, 2026 89.28%
September 02, 2026 95.32%
September 01, 2026 104.9%
August 31, 2026 96.10%
August 28, 2026 94.16%
August 27, 2026 92.23%
August 26, 2026 91.86%
August 25, 2026 104.4%
August 24, 2026 98.30%
August 21, 2026 95.59%
Date Value
August 20, 2026 93.73%
August 19, 2026 100.1%
August 18, 2026 74.43%
August 17, 2026 78.84%
August 14, 2026 78.91%
August 13, 2026 68.78%
August 12, 2026 92.40%
August 11, 2026 75.92%
August 10, 2026 72.24%
August 07, 2026 66.31%
August 06, 2026 67.21%
August 05, 2026 67.74%
August 04, 2026 58.43%
August 03, 2026 50.92%
July 31, 2026 51.08%
July 30, 2026 53.64%
July 29, 2026 60.29%
July 28, 2026 53.23%
July 27, 2026 52.38%
July 24, 2026 53.00%
July 23, 2026 54.05%
July 22, 2026 64.59%
July 21, 2026 69.34%
July 20, 2026 67.14%
July 17, 2026 65.09%

Total Return Definition

The Total return is the change in price over a specific period of time that includes dividends and distributions paid.

Read full definition.

1 Year Total Returns (Daily) Range, Past 5 Years

View 1 Year Total Returns (Daily) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

1 Year Total Returns (Daily) Benchmarks

View 1 Year Total Returns (Daily) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. -2.50%
Alnylam Pharmaceuticals, Inc. -43.07%
Anika Therapeutics, Inc. 126.3%
Savara, Inc. 44.09%
Vericel Corp. 33.08%